Therefore, the combined blockade of TGFβ and PD-1/PD-L1 may provide clinically meaningful responses in some patients with MSI and MSS CRC, possibly by making the immunosuppressive TME sensitive to ICIs. The gene discussed is TGFB1; the disease is colorectal carcinoma.